Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: A prospective randomised controlled single centre study

British Journal of Cancer

Volumn 89, Issue 1, 2003, Pages 43-49

  Innes, H E ^a   Smith, D B ^a   O'Reilly, S M ^a   Clark, P I ^a   Kelly, V ^a   Marshall, E ^a  

^a Clatterbridge Centre for Ontology   (United Kingdom)

Author keywords

Febrile neutropenia; Low risk; Oral antibiotics; Outpatient

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CIPROFLOXACIN; GENTAMICIN; PIPERACILLIN PLUS TAZOBACTAM;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTPATIENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; FEMALE; FEVER; HUMANS; INFUSIONS, INTRAVENOUS; LENGTH OF STAY; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; OUTPATIENTS; PATIENT DISCHARGE; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 0042846028     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600993     Document Type: Article

References (33)

1. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, Kaasa S, Klee M, Osoba D, Razavi D, Rofe PS, Schraub S, Sneeuw K, Sullivan M, Takeda F (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85: 365-376
2. Bodey GP (1966) Fungal infections complicating acute leukemia. J Chronic Dis 19: 667-687
3. Bodey GP, Buckley M, Sathe YS, Freireich EJ (1966) Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64: 328-340
4. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J, Eckberg K, Lloyd S, Purl S, Blendowski C, Goodman M, Barnicle M, Stewart I, McHale M, Bonomi P, Kaplan E, Taylor S, Thomas CR, Harris J (1993) The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 11: 570-579
5. Cometta A, Zinner S, de Bock R, Calandra T, Gaya H, Klastersky J, Langenaeken J, Paesmans M, Viscoli C, Glauser MP (1995) Piperacillintazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrob Agents Chemother 39: 445-452
6. de Haes JC, van Knippenberg FC, Neijt JP (1990) Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. Br J Cancer 62: 1034-1038
7. Dranitsaris G, Tran TM, McGeer A, Narine L (1995) Pharmacoeconomic analysis of empirical therapy with ceftazidime alone or combination antibiotics for febrile neutropenia in cancer patients. Pharmacoeconomics 7: 49-62
8. Elting LS, Cantor SB (2002) Outcomes and costs of febrile neutropenia: adventures in the science and art of treatment choices. Support Care Cancer 10: 189-196
9. Elting LS, Rubenstein EB, Rolston K, Cantor SB, Martin CG, Kurtin D, Rodriguez S, Lam T, Kanesan K, Bodey G (2000) Time to clinical response: an outcome of antibiotic therapy of febrile neutropenia with implications for quality and cost of care. J Clin Oncol 18: 3699-3706
10. Elting LS, Rubenstein EB, Rolston KV, Bodey GP (1997) Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis 25: 247-259
11. Feld R, Paesmans M, Freifeld AG, Klastersky J, Pizzo PA, Rolston KV, Rubenstein E, Talcott JA, Walsh TJ (2002) Methodology for clinical trials involving patients with cancer who have febrile neutropenia: updated guidelines of the Immunocompromised Host Society/Multinational Association for Supportive Care in Cancer, with emphasis on outpatient studies. Clin Infect Dis 35: 1463-1468
12. Freifeld A, Marchigiani D, Walsh T, Chanock S, Lewis L, Hiemenz J, Hiemenz S, Hicks JE, Gill V, Steinberg SM, Pizzo PA (1999) A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 341: 305-311
13. Gardembas-Pain M, Desablens B, Sensebe L, Lamy T, Ghandour C, Boasson M (1991) Home treatment of febrile neutropenia: an empirical oral antibiotic regimen. Ann Oncol 2: 485-487
14. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL, Young LS (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34: 730-751
15. Hughes WT, Armstrong D, Bodey GP, Brown AE, Edwards JE, Feld R, Pizzo P, Rolston KV, Shenep JL, Young LS (1997) 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis 25: 551-573
16. Hughes WT, Armstrong D, Bodey GP, Feld R, Mandell GL, Meyers JD, Pizzo PA, Schimpff SC, Shenep JL, Wade JC, Young LS, Yow MD (1990) From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 161: 381-396
17. Kern WV, Cometta A, De Bock R, Langenaeken J, Paesmans M, Gaya H (1999) Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 341: 312-318
18. Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B, Rolston K, Talcott J (2000) The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18: 3038-3051
19. Leese B (1993) The costs of treating febrile neutropenia in six U.K. Hospitals. Eur J Cancer 29A(Suppl 7): S15-S18
20. Malik IA, Abbas Z, Karim M (1992) Randomised comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients. Lancet 339: 1092-1096
21. Malik IA, Khan WA, Karim M, Aziz Z, Khan MA (1995) Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial. Am J Med 98: 224-231
22. Marshall E, Smith DB, O'Reilly SM, Murray A, Kelly V, Clark PI (2000) Low-dose continuous-infusion ceftazidime monotherapy in low-risk febrile neutropenic patients. Support Care Cancer 8: 198-202
23. Ozer H, Armitage JO, Bennett CL, Crawford J, Demetri GD, Pizzo PA, Schiffer CA, Smith TJ, Somlo G, Wade JC, Wade III JL, Winn RJ, Wozniak AJ, Somerfield MR (2000) 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 18: 3558-3585
24. Pizzo PA, Hathorn JW, Hiemenz J, Browne M, Commers J, Cotton D, Gress J, Longo D, Marshall D, McKnight J, Rubin M, Skelton J, Thaler M, Wesley R (1986) A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 315: 552-558
25. Rolston KV, Berkey P, Bodey GP, Anaissie EJ, Khardori NM, Joshi JH, Keating MJ, Holmes FA, Cabanillas FF, Elting L (1992) A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med 152: 283-291
26. Rubenstein EB, Rolston K, Benjamin RS, Loewy J, Escalante C, Manzullo E, Hughes P, Moreland B, Fender A, Kennedy K, Holmes F, Elting L, Bodey GP (1993) Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer 71: 3640-3646
27. Rubin M, Hathorn JW, Pizzo PA (1988) Controversies in the management of febrile neutropenic cancer patients. Cancer Invest 6: 167-184
28. Sanders JW, Powe NR, Moore RD (1991) Ceftazidime monotherapy for empiric treatment of febrile neutropenic patients: a meta-analysis. J Infect Dis 164: 907-916
29. Talcott JA, Finberg R, Mayer RJ, Goldman L (1988) The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Arch Intern Med 148: 2561-2568
30. Talcott JA, Siegel RD, Finberg R, Goldman L (1992) Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 10: 316-322
31. Talcott JA, Whalen A, Clark J, Rieker PP, Finberg R (1994) Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule. J Clin Oncol 12: 107-114
32. Viscoli C, Bruzzi P, Castagnola E, Boni L, Calandra T, Gaya H, Meunier F, Feld R, Zinner S, Klastersky J, Glauser M (1994) Factors associated with bacteraemia in febrile, granulocytopenic cancer patients. The International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC). Eur J Cancer 30A: 430-437
33. Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67: 361-370